Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 68220-0118
Overview of NDC 68220-0118
NDC 68220-0118 corresponds to Adalimumab (Humira), a biologic agent used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Since its approval, Humira has dominated the biologic market segment, with extensive patent protections and a broad clinical application portfolio.
Market Size and Trends
Global Market Valuation:
The biologics market for autoimmune disorders was valued at approximately $300 billion in 2021. Adalimumab accounted for roughly 40% of this segment, reflecting peak sales estimated at $21.2 billion in 2021.[1]
Market Growth Drivers:
- Increasing prevalence of autoimmune diseases globally.
- Expanded indications: recent approvals include hidradenitis suppurativa, uveitis, and Crohn’s disease.
- Growing adoption in developing markets due to expanding healthcare infrastructure.
- Patent expirations for Humira in key markets (e.g., the U.S. in 2023) accelerate generic and biosimilar competition.
Competitive Landscape:
Post-patent expiration, biosimilars have entered markets in the U.S. (Amgen’s Amjevita, Sandoz’s Hyrimoz, etc.), Europe, and other regions. These biosimilars typically retail at 15-35% below brand name prices, impacting overall market share and pricing strategies.[2]
Price Dynamics
Historical Pricing (Humira):
- U.S. wholesale acquisition cost (WAC) in 2020 averaged around $5,600 per month for a standard dose.[3]
- List prices have been stable historically, but discounts and rebates reduce actual payer costs.[4]
Post-Patent Price Trends:
- Biosimilar entry led to a 20-30% price reduction within the first year of competitive launch.
- Official biosimilar list prices range from $4,200 to $4,700 per month.
Reimbursement and Network Effects:
- Payer negotiations heavily influence final patient cost.
- Prior authorization and formulary restrictions are standard to manage biosimilar adoption.
Price Projections (2023-2027)
| Year |
Estimated Average Monthly Price (USD) |
Notes |
| 2023 |
$4,750 |
Launch of biosimilars accelerates; steady market share for biosimilars. |
| 2024 |
$4,500 |
Increased biosimilar competition further pressures price. |
| 2025 |
$4,200 |
Biosimilar volume growth; possible label expansions or therapeutic pipelines. |
| 2026 |
$4,000 |
Price stabilization; margins may compress with additional biosimilars. |
| 2027 |
$3,800 |
Continued biosimilar proliferation; generic market maturity. |
Factors Influencing Future Pricing
- Patent Litigation and Market Entry: Patent litigations can delay biosimilar launch or impact pricing strategies.
- Regulatory Policies: Policies promoting biosimilar substitution can increase competition.
- Market Penetration: Greater biosimilar adoption reduces the average price of the class.
- Manufacturing Costs: Advances in biomanufacturing may lower costs despite complex production processes.
Regulatory and Policy Environment
- U.S.: Patent expiry in 2023 led to biosimilar launches with some market share penetration. The Biosimilar Price Competition and Innovation Act influences approval and pricing policies.[5]
- Europe: Biosimilars have maintained a significant share, with some countries witnessing discounts of up to 60% compared to the originator.[6]
- Other Markets: Regulations vary; Asia and Latin America exhibit varied biosimilar acceptance and pricing.
Investment and R&D Considerations
Pharmaceutical companies are investing in pipeline biosimilars and next-generation biologics to expand therapeutic options. Patent expiry pressures increase the focus on developing enhanced versions or alternative mechanisms to sustain revenue streams.
Key Takeaways
- The market for adalimumab is transitioning from high-priced brand dominance to biosimilar competition.
- Average monthly prices for biosimilars are expected to stabilize around $3,800 to $4,200 by 2027.
- Price reductions will be driven by biosimilar availability, regulatory policies, and market share shifts.
- Existing patents and intellectual property litigation remain critical determinants of near-term pricing stability.
- Strategic pricing adjustments are necessary for manufacturers to maintain competitiveness in the generic biosimilar era.
FAQs
1. How does biosimilar entry impact the price of adalimumab?
Biosimilar entry typically results in a 20-35% reduction in list prices within the first year, with further discounts possible as market penetration increases.
2. What are the main regulatory hurdles for biosimilar approval?
Biosimilars require demonstrating similarity in quality, safety, and efficacy to the reference product. Regulatory agencies like the FDA and EMA require comprehensive analytical, clinical, and manufacturing data.
3. Will the price of Humira return to pre-patent levels?
The original Humira price is unlikely to return due to biosimilar competition and payer negotiations. Prices are expected to remain lower and stabilize over time.
4. How do reimbursement policies influence biosimilar adoption?
Payers often favor biosimilars due to lower costs, implementing formulary preferences and prior authorization protocols to promote their utilization.
5. What future developments could alter price projections?
New indications, patent litigation outcomes, healthcare policy changes, or breakthroughs in biologic manufacturing could significantly influence future prices.
References
- IQVIA. Global Biologics Market Report (2022).
- EvaluatePharma. Biosimilar Market Analysis (2022).
- Red Book. Average Wholesale Price of Humira (2020).
- CMS. Medicare Part B Drug Rebates (2021).
- U.S. FDA. Biosimilar Development and Approval (2022).
- European Medicines Agency. Biosimilar Medicines (2022).
